GSK brings Johns Hop­kins prof and Blade co-founder on board; Evotec sets terms for $575M+ US IPO

GlaxoSmithKline CEO Emma Walmsley is adding another scientist to the company’s board. Early Wednesday — alongside their Q3 update — Walmsley put out word that Harry “Hal” Dietz, a professor of …
( read original story …)